CClinicalTrials.gg
CompletedNCT04530773Updated Jun 11, 2025

Developing and Validating VR-Enabled Ophthalmic Clinics: A New Paradigm for Visual Function Testing

An interventional study of Watch VR movies/ Play VR games in Visual Health of Virtual Reality, sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. Completed at 1 site in China. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-11.

Sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University · Not applicable, Interventional, and Health services research

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

This study aimed to design and validate a VR-based ophthalmic clinic that replicates traditional tests of visual acuity, stereopsis, and contrast sensitivity within an immersive digital environment. Using a rigorously developed system based onprogrammable interfaces, and standardized testing paradigms, we compared VR assessments against gold-standard clinical tools in a cohort of healthy adult participants. Key outcomes included test consistency, correlation, user acceptability, visual fatigue, and time efficiency. Our findings offer evidence for the viability of VR as a platform for remote ophthalmic testing and pave the way for scalable digital eye care delivery.

02

Conditions studied

  • Visual Health of Virtual Reality
03

In context

Lead sponsor

Zhongshan Ophthalmic Center, Sun Yat-sen University is the lead sponsor of 159 studies on the registry; 77 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • The study included healthy individuals older than 18 years of age with a best-corrected visual acuity (BCVA) of \<0.1 logarithm of minimum angle of resolution (logMAR) and no ongoing or prior history of ocular or systemic disease.

Exclusion criteria

Exclusion Criteria:

  • The study excluded healthy individuals younger than 18 years of age with a best-corrected visual acuity (BCVA) of >0.1 logarithm of minimum angle of resolution (logMAR) with ongoing or prior history of ocular or systemic disease.
05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    GROUP1

    Behavioral: Watch VR movies/ Play VR games

  • Experimental
    GROUP2

    Behavioral: Watch VR movies/ Play VR games

  • Experimental
    GROUP3

    Behavioral: Watch VR movies/ Play VR games

  • Experimental
    GROUP4

    Behavioral: Watch VR movies/ Play VR games

  • Experimental
    GROUP5

    Behavioral: Watch VR movies/ Play VR games

Interventions

  • BehavioralWatch VR movies/ Play VR games

    The healthy individuals will watch VR movies or play VR games with different Physical parameters for 60 minutes.

06

What researchers measure

Primary outcomes

  1. Accommodative Response

    The actual amount of accommodation that exists is measured with a skiascope

    Time frame: 60 min

  2. AC/A Ratio

    The ratio of accommodation convergence to accommodation is measured and calculated by maddox

    Time frame: 60 min

07

Study locations

1 site
  • Zhongshan Opthalmic Center
    Guangzhou, Guangdong 510000, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04530773
Lead sponsor
Zhongshan Ophthalmic Center, Sun Yat-sen University
Responsible party
Jin Yuan (Clinical Professor, Zhongshan Ophthalmic Center, Sun Yat-sen University) — Principal investigator
First posted
Aug 28, 2020
Start date
Jan 1, 2024
Primary completion
Dec 31, 2024
Completion
Dec 31, 2024
Last update
Jun 11, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion